A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model

Abstract Objective To investigate the effects of V1A receptor antagonist through inhibition of vasopressin-induced VEGF secretion in an experimental model. Study design Thirty rats were randomly divided into five groups. Four groups were given 10 IU pregnant mare serum gonadotropin/day (sc) at 8:00–...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of obstetrics & gynecology and reproductive biology 2014-03, Vol.174, p.86-90
Hauptverfasser:	Cenksoy, Cahit, Cenksoy, Pinar Ozcan, Erdem, Ozlem, Sancak, Banu, Gursoy, Rifat
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antidiuretic Hormone Receptor Antagonists Ascitic Fluid - chemistry Chorionic Gonadotropin - administration & dosage Corpus Luteum Disease Models, Animal Female Follicular Atresia Gonadotropin-Releasing Hormone - antagonists & inhibitors Gonadotropins, Equine - administration & dosage Indoles - administration & dosage Obstetrics and Gynecology OHSS Organ Size Ovarian Hyperstimulation Syndrome - pathology Ovarian Hyperstimulation Syndrome - physiopathology Ovarian Hyperstimulation Syndrome - prevention & control Ovary - pathology Ovulation Induction - adverse effects Ovulation Induction - methods Prevention Pyrrolidines - administration & dosage Rats Rats, Wistar Relcovaptan V1a receptor antagonist Vascular Endothelial Growth Factor A - analysis Vascular Endothelial Growth Factor A - secretion Vasopressins - physiology VEGF Weight Gain
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!